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INTRODUCTION 
 
The introduction of d-tubocurarine - a neuromuscular blocking 
drug, by Griffith and Johnson1 in 1942 revolutionized clinical anaesthesia. 
The use of muscle relaxants became a vitally important aspect of modern 
anaesthesia practice. In 1967, Baird and Reid2 first reported on the clinical 
administration of the synthetic amino steroid pancuronium. 
 
Development of the intermediate acting neuromuscular blockers 
was built on compound metabolism and resulted in the introduction of 
vecuronium, an aminosteroid,and atracurium, a benzylisoquinolium, in the 
1980s. The lack of cardiovascular effects of vecuronium and degradation 
of atracurium by Hoffmann elimination, reduced the effects of biologic 
disorders such as advanced age or organ failure on the  pattern of 
neuromuscular blockade. Despite the above mentioned neuromuscular 
blocking drugs, succinylcholine still remains the favorite for achieving 
rapid, evanescent relaxation despite its dangers of triggering malignant 
hyperthermia, producing hyperkalemia3 in susceptible patients, raising 
intra ocular pressure,raising intra cranial pressure and muscle pains4,5 in 
many. 
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Although succinylcholine is a reliable agent due to its rapid onset, 
its numerous side effects led to the search of newer muscle relaxants  with 
a similar onset of action6,7. The technique of administering established non 
depolarizing muscle relaxants has been variously modified in an attempt 
to reduce its onset time. 
 
Rocuronium is the first non-depolarizing relaxant considered  to  be 
an acceptable substitute for succinylcholine in facilitating rapid tracheal 
intubation8,9,10. Ephedrine is an sympathomimetic drug which acts on 
alpha1 and beta receptors. 
 
It acts as agonist at these receptors and increases cardiac output and 
muscle blood flow.11 It increases the oxygen consumption of tissues but 
cardiac output is also increased to meet the demand12,13 
The onset time of muscle relaxants is partly determined by  the speed 
with which these drugs reach the neuromuscular junction. 
 
This concept is used in the present study in which the effect of 
Intravenous Ephedrine on the onset time and Intubating conditions of 
Rocuronium bromide was studied. 
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AIM OF THE STUDY 
 
To compare the Effect of intravenous “Ephedrine” on the onset of 
action of Rocuronium and intubating conditions with a “placebo”. 
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ANATOMY OF NEUROMUSCULAR JUNCTION 
 
 
Over a century ago, CLAUDE BERNARD inferred that excitation 
of the muscle was caused by a chemical transmitter at  the  neuromuscular 
junction. The Central nervous system controls muscle activity through its 
motor innervation, the connecting link between the two being the 
neuromuscular junction where the chemical signals from the nerve are 
converted into action potentials in the muscle. 
 
MOTOR UNIT 
 
 
Each motor neuron runs without interruption from the  ventral  horn 
of the spinal cord to the neuromuscular junction.A single anterior horn 
cell,its axon, the axonal branches and the group of muscle fibres innervated 
constitute a MOTOR UNIT. 
 
THE END PLATE 
 
The mammalian neuromuscular junction is compact and extends 
about 10 um above the muscle membrane. Macroscopically all  the  motor 
nerve pierce the muscle at a point between the origin and  insertion- The 
Motor point. It then breaks up into the neurofibrils which innervate the 
muscle.Most muscle fibers in human beings are focally innervated (i.e.,) 
they receive innervation at the focal point-The motor 
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end plate. (EN Plaque endings). However tonic muscles such  as  the extra 
ocular muscles,the facial muscles and the intrinsic laryngeal muscles are 
multiply innervated with several motor end plates  distributed over the 
muscle fibers (En Grappe endings). 
 
JUNCTIONAL CLEFT 
 
 
It is a gap of 20nm that separates the nerve from the surface of the 
muscle. The whole neuromuscular junction is surrounded by a  membrane 
which is closely adherent to the nerve, termed the schwann cell 
membrane.It is this membrane that separates the synaptic cleft from the 
extracellular fluid. The muscle surface is heavily corrugated at the 
neuromuscular junction and the deep invaginations of the  junctional  cleft 
into the muscle. The secondary clefts are separated by the  junctional folds 
on the surface. Thus the surface area of the junctional cleft is increased. 
Around the crest of the secondary cleft is a zone rich  in cholinesterase. 
The shoulders of the fold are densely populated with choline 
receptors.Each neuromuscular end plate has 106 - 107 nicotinic receptors. 
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PERIJUNCTIONAL ZONE 
 
 
It is a narrow transitional zone separating the membrane of the 
junction from the rest of the muscle .It is a critical area where the potential 
developed at the end plates is converted to an action potential that sweeps 
the muscle to initiate contraction. 
 
THE VESICLES 
 
 
These are synthesized in the cell bodies of the lower motor  neurons 
in the spinal cord or the brain stem and reach the nerve terminal by axon 
transport. Acetylcholine is synthesized in the terminal axoplasm and 
loaded into these vesicles which are lined up along the synaptic  cleft. Each 
of these vesicles contains 6000-8000 molecules of acetylcholine. 
 
PREJUNCTIONAL RECEPTORS 
 
 
They are cylindrical assemblages of protein sub units located in the 
nervous system. These receptors may be blocked by d-tubocurarine.  They 
control an ion channel specific for sodium. The non depolarizing agents 
block the opened channels of these receptors. 
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POST JUNCTIONAL RECEPTORS 
 
 
These are two types-junctional and extra junctional receptors. 
 
 
JUNCTIONAL RECEPTORS 
 
 
These are concentrated in the end plate on the shoulders of the 
junctional folds. The junctional receptors are found in the motor end plates 
of muscles in normal adults. They are generally assumed to be the 
receptors for acetylcholine. The receptor is a glycoprotein with a molecular 
weight of 2,50,000 and is made of (2:1:1:1) subunits. The five sub units 
are linear and arranged to form a potential tube or ion channel through the 
receptors. This channel is opened when two acetylcholine or other agonist 
molecules attach to the ACh binding sites on alpha units, and cause the 
subunits to rotate into a new conformation. 
 
EXTRA JUNCTIONAL RECEPTORS 
 
 
The subunit composition is α,β,γ and δ in a ratio of 2: 1: 1: 1.  They 
are not usually present in muscles of normal adults. They are not restricted 
to the end plate, but spread over the entire surface of the muscle. They are 
more responsive to depolarizing agents and less responsive to non 
depolarizing agents. 
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THE MUSCLE 
 
 
The contractile elements of the muscle cells are the myofilament- 
the thick myosin filaments and thin actin filaments with attached  troponin 
and tropomyosin. These filaments interdigitate and slide over each other 
when the muscle contracts. The myofilamets are grouped into myofibrils. 
Surrounding the myofibrils is the sarcoplasmic reticulum, which acts as a 
reservoir for calcium. The sarcoplasmic reticulum comes into close 
proximity with the transverse tubules. These tubules convey the electrical 
impulse from the muscle into the sarcoplasmic reticulum, thereby 
triggering the liberation of calcium and the contraction of the myofilament. 
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PHYSIOLOGY OF NEUROMUSCULAR 
TRANSMISSION 
The transmission of impulses from the nerve to the muscle is 
mediated by acetylcholine,released by depolarization of the motor nerve 
terminal. 
 
SYNTHESIS OF ACETYL CHOLINE 
 
 
Acetylcholine is synthesized by a specific enzyme called choline 
acetyl transferase, from choline and acetylCoA. This enzyme is 
synthesized in the perikaryon and migrates along the  cholinergic  neurons 
to the nerve terminals. 
 
The synthesis of acetylcholine requires the presence of choline, 
acetyl CoA, ATP,Glucose and calcium. Acetyl CoA and ATP  are  formed 
in the mitochondria and glucose is present in the cytoplasm. The choline 
necessary for this process is derived from the extra cellular fluid,from 
which it is transported to the nerve terminal by a specific carrier mediated 
transport system. This transport is inhibited by hemicholinium. The extra 
cellular choline is partly derived from hydrolysed acetyl choline and partly 
from the diet. 
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STORAGE OF ACETYL CHOLINE 
 
 
Acetylcholine is stored in minute vesicles 30-60nm in diameter 
(quantals). These vesicles are present in large numbers in the nerve 
terminals near the synaptic surface. Each vesicle holds one quantum of 
transmitter, each having 6000-8000 molecules of acetylcholine. 
 
There is always some free acetylcholine present in the cytoplasm 
(non quantal) 
 
The quantal form could be in the reserve store (  R-ACH) or as  part 
of an immediate available source (IAS-ACH). Acetylcholine contained in 
the vesicle constitutes the releasable pool. Acetylcholine of the axoplasm 
is the non releasable or the stationary ACh. 
 
RELEASE OF ACETYL CHOLINE 
 
 
Acetylcholine is released from the nerve terminal both 
spontaneously and as a result of depolarization. The random release of the 
transmitter from the motor nerve ending  causes  1-2mv depolarization of 
the motor end plate. This causes the ‘miniature end plate potentials’ 
(MEPPS). As the MEPPS are so small, they do not generate an action 
potential. 
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When the end plate potential reaches a certain critical magnitude, it 
depolarizes these surface membrane of the muscle fibre and sets up a 
propagated action potential. Calcium entry begins when the action 
potential approaches the maximum, and continues until the membrane 
potential is returned to normal by the outward flux of potassium. 
 
REMOVAL OF ACETYL CHOLINE 
 
 
This is brought out by: 
 
 
1) DIFFUSION 
 
 
Diffusion is almost rapid enough to account for the rapid rate of 
decay in the action of acetyl choline. 
 
2) ACETYL CHOLINESTERASE 
 
 
It is an asymmetric protein found in high concentrations in all   post 
synaptic clefts related to cholinergic neurons. Each molecule of the 
enzyme is able to bind and hydrolyse several molecules of acetyl  choline. 
The active site of this enzyme consists of an anionic subsite and an ester 
binding sub site. Hydrolysis of acetylcholine involves the formation of a 
reversible enzyme-substrate complex followed by the acetylation of the 
esteratic sub site and release of choline into solution. 
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3) REUPTAKE OF ACETYL CHOLINE 
 
 
This is insignificant but choline uptake is essential for acetylcholine 
synthesis. 
 
THE MEMBRANE POTENTIAL AND DEPOLARISATION 
 
 
At rest the membrane potential of -90mv is maintained by the 
sodium-potassium adenosine phosphatase pump, which provides the 
energy necessary for the active transport mechanism. This resting 
membrane potential of -90 mv is the result of an excess of positively 
charged ions outside the cell relative to the inside of the cell.  This uneven 
distribution is the consequence of the greater permeability of the potassium 
relative to sodium. Potassium tends to pass out of the cell along the 
concentration gradient in the resting state (l50mmol inside the cell to about 
5 mmol outside). The binding of the two molecules of  acetyl choline to 
the two a subuits of the cholinergic receptor induces a conformational 
change in the proteins of the receptor. This results in the opening of 
channels in the receptor complex which allows cations to  flow through thr 
membrane along the concentration and electrical gradients. 
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Though all the cations sodium , potassium and calcium may pass 
through channel, the most important change is a net inward flow of 
sodium. As a result of this,the transmembrane potential changes from - 90 
mv to 0 or + 10mv and the end plate potential is produced. When the 
magnitude of the depolarization exceeds the critical threshold level (40- 
45mv) a propagated action potential occurs.By the way of T - Tubules the 
action potential reaches the sarcoplasmic reticulum from which calcium is 
released and muscle contraction is initiated. 
 
Towards the end of depolarization, potassium conductance 
increases as sodium conductance falls back to its resting level and an 
excess of intra cellular sodium is expelled by means of the sodium pump 
mechanism charged ions outside the cell relative to the inside of the cell. 
This uneven distribution is the consequence of the greater permeability  of 
the potassium relative to sodium. Potassium tends to pass out of the cell 
along the concentration gradient in the resting state (l50mmol inside the 
cell to about 5 mmol outside). The binding of the two molecules of acetyl 
choline to the two a subuits of the cholinergic receptor induces a 
conformational change in the proteins of the receptor. This results in the 
opening of channels in the receptor complex which allows cations to  flow 
through thr membrane along the concentration and electrical gradients. 
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Though all the cations sodium , potassium and calcium may pass 
through channel, the most important change is a net inward flow of 
sodium. As a result of this,the transmembrane potential changes from - 90 
mv to 0 or + 10mv and the end plate potential is produced. When the 
magnitude of the depolarization exceeds the critical threshold level (40- 
45mv) a propagated action potential occurs.By the way of T - Tubules the 
action potential reaches the sarcoplasmic reticulum from which calcium is 
released and muscle contraction is initiated. 
 
Towards the end of depolarization, potassium conductance  increases 
as sodium conductance falls back to its resting level and an excess of intra 
cellular sodium is expelled by means of the sodium pump mechanism 
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PHARMACOLOGY OF ROCURONIUM BROMIDE 
 
 
 
 
 
Originally synthesized and studied in the Organon and Teknika 
laboratories as ORG 9426.Introduced into clinical practice in 1994. 14 
CHEMISTRY 
 
 
Rocuronium is a steroidal muscle relaxant of  intermediate 
duration of action. It is the 2-morpholino, 3-hydroxy, 16N - allyl 
-pyrrolidino derivative of vecuronium.l - [ (2b,3a,5a,16b,17b)-17-- (acetyl 
oxy) -3-hydroxy-2- (4-morpholinyl)-androstan-16-yl (2propenyl) 
pyrrolidium bromide. 
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ROUTES OF ADMINISTRATION 
 
 
Rocuronium can be administered by intravenous and 
intramuscular routes. 
 
DOSES 
 
ED95-0.3mg/kg 
 
· Intubation at 60-90 sec-0.6-0.9mg/kg 
 
· Relaxation (N20/02)-0.3-0Amg/kg 
 
· Relaxation (inhalational agent)-0.2-0.3mg/kg , 
 
· Maintenance-0.1-0.15 mg/kg 
 
· Infusion-8-12/kg/min 
I.M 
· Infants-l mg/kg 
 
· Children-1.8mg/kg 
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MECHANISM OF ACTION 
 
 
Rocuronium is a non-depolarizing neuromuscular blocking agent 
with a rapid onset of action, depending on dose. It has an intermediate 
duration of action. Rocuronium produces neuromuscular blockade by 
competing with acetylcholine for cholinergic receptors at the motor end 
plate. It is 7-8 times less potent than vecuronium.A greater number of drug 
molecules are able to reach junctional receptors within a fewer circulation 
times, enabling faster development of neuro muscular blockade. Low 
potency leads to a weaker binding to receptors and prevents buffered 
diffusion, a process that occurs with potent drugs, which causes repetitive 
binding and unbinding to receptors. Diffusion of less potent drugs away 
from the receptors very likely occurs much more readily, thereby helping 
to limit the duration of blocking effect. This is the most likely reason why 
the duration of action of rocuronium remains intermediate. 
 
ONSET OF ACTION 
 
 
ED90-is the dose required to produce 90% depression of the  twitch 
response of the thumb to stimulation of the ulnar nerve. With doses of 0.6 
mg rocuronium per kg of body weight administered over 5 
20  
sec; effective intubating conditions are achieved within 60 to 90 seconds.7,8 
Onset of action of rocuronium may be delayed in patients  with conditions 
such as cardiovascular disease and advanced age, which are associated 
with a slowed circulation. The onset of action is faster in infants and 
children than in adults. 
 
When i.m. route is chosen in infants and in children, tracheal 
intubation can be performed in 2.5-3 mins with a duration of action of 2 
hours. 
 
TIME TO PEAK EFFECT 
 
 
The time to peak effect is depend on dosage, the age of the  patient, 
and the anaesthetic administered concurrently. The  median  times to 
maximum block are given below. 
 
Adults 18-64 yrs of age under opioid-nitrous oxide-oxygen 
anaesthesia 
 
0.4mg/kg:3 minutes (range,1.3-8.2) 
 
 
0.6mg/kg:1.8 minutes (range,0.6-13)0.9mg/kg: 1.4 minutes 
(range,0.8-6.2) 
 
1.2mg/kg:1 minute (range,0.6-4.7) 
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DURATION OF ACTION 
 
 
The clinical duration of action (the duration until spontaneous 
recovery to 25% of control twitch height) with 0.6 mg/kg is 30-40min. 
 
The total duration (time until spontaneous recovery to 90% of 
control twitch height) is 50 min. 
 
The mean time of spontaneous recovery of twitch response from 
25%-75% (recovery index) after a bolus dose of 0.6mg/kg is 14min.As the 
dose is increased,the recovery slows. The duration of action is also limited 
by avid liver uptake and elimination into bile, due to an increase in the 
lipophilic nature of the molecule with respect to vecuronium. Duration of 
clinical effect (the time until spontaneous return of the  twitch response to 
250/0 of control value is determined using a  peripheral nerve stimulator) 
is dependent on dosage. Median time to spontaneous recovery from 250/0 
to 75% of the control value is 13 min in adults. During rapid sequence 
induction of anaesthesia under propofol or fentanyl/thiopental anaesthesia, 
adequate intubating conditions are achieved with in 60 secs, in 96% of the 
patients, following a dose of 1 mg/kg of rocuronium bromide.Of these 70% 
are rated excellent. 
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Following a dose of 0.6mg/kg , adequate intubating conditions are 
achieved with in 60 seconds, in 81 % and 75% of the patients during a 
rapid sequence induction techniques with propofol or fentanyl / 
thiopentone respectively. 
 
The clinical duration of action is shorter in childrens than in  adults. 
 
 
With doses higher than 1 mg/kg, intubating conditions will not 
improve appreciably. However the duration of action will be prolonged. 
 
Adults 18 to 64 years of age- 
 
 
• 0.45 mg/kg- 22 minutes (12-31) 
 
 
• 0.6 mg/kg -31 minutes (15-85) 
 
 
• 0.9 mg/kg-58 minutes (27-111) 
 
 
• 1.2 mg/kg-67 minutes (38-160) 
 
 
MAINTENANCE DOSE 
 
 
0.075-0.15 mg/kg give when the twitch height has recovered to 25% 
of control twitch height, or when 2 or 3 responses to TOF  is present. No 
cumulation of effect with repetitive maintenance dosing at 
the recommended level has been observed. 
23  
CONTINUOUS INFUSION 
 
 
A loading dose of 0.6 mg/kg is administered, and the infusion is 
started at 0.3-0.6 mg/kg/hr, when the neuromuscular function starts to 
recover. The infusion rate should be adjusted to maintain the twitch 
response at 10% control twitch height or to maintain 1 or 2 responses to 
TOF. 
 
DISTRIBUTION 
 
 
Rocuronium has a biphasic distribution . The rapid distribution half 
life is 1-2 minutes and the slower distribution half life is 14-18 minutes. 
Approximately 80% of the initial rocuronium dose is redistributed. As 
administration of rocuronium continues, tissue compartments filled with 
in 4-8 hours, less rocuronium is redistributed away from the site of action, 
and the dosage required to maintain neuromuscular blockade via 
continuous infusion falls to about 20% of  the initial infusion rate. 
 
• Volume of distribution -203 ml/kg (193-214) 
 
 
• Clearance -3.71 ml/kg/min (3.5-3.9) 
 
 
• Plasma half life-73 min (66-80) 
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PROTEIN BINDING 
 
Low (30%) 
 
BIOTRANSFORMATION 
 
Deacetylated in the liver to 17 - desacetyl - rocuronium (ORG 9943) 
and 16 N desallyl rocuronium (ORG 20860), these are usually not 
detectable in plasma and therefore not expected to contribute significantly 
to pharmacodynamic effects of rocuronium. 
 
ELIMINATION 
 
 
Rocuronium is primarily eliminated by the liver, with the small 
fraction (10%) eliminated by the kidneys. It is taken up in to the liver by a 
carrier mediated active transport system. Rocuronium is excreted in urine 
and bile. Excretion in urine approaches 40% with in 12-24 hours 
 
HEPATIC DISEASE 
 
 
In hepatic disease (most commonly cirrhosis) the volume of 
distribution of rocuronium is increased and clearance is decreased. The 
duration of action is prolonged and the onset may be prolonged. 
Consequently dose in patients with hepatic disease should be conservative 
and guided by careful monitoring of neuromuscular functions. 
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Adult and geriatric patients with normal hepatic functions: 
 
1.4 ±0.04 hrs during opiod- nitrous oxide- oxygen anaesthesia and 
2.4±0.08 hrs during isoflurane anaesthesia. 
Adults and geriatric patients with hepatic function impairment: 
4.3±6hrs during isoflurane anaestheia. 
RENAL FAILURE 
 
In patients with renal failure, the plasma clearance of rocuronium 
may be decreased and its volume of distribution is increased. The duration 
of action of single and repeated dose is not significantly affected. In the 
elderly the clearance is decreased and the volume of distribution is 
increased with a consequent prolongation in duration of action. 
CARDIOVASCULAR EFFECTS 
 
The cardiovascular effects of muscle relaxants may be produced 
 
by 
 
1. Muscarinic receptor block 
2. Ganglionic block 
3. Increased noradrenaline release 
4. Blockade of noradrenaline reuptake 
5. Histamine liberation 
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Initial animal studies with rocuronium suggested the occurrence  of 
muscarinic receptor and ganglionic blocking effects only with the doses 
that are much higher than the dose required for neuromuscular blockade. 
Further studies in dogs conformed that cardiovascular effects were 
minimal with the doses of up to 3xED 95, although heart rate tended to 
increase with the doses greater than 5xED 95. 
 
Routine measurements of heart rate and the arterial pressure  during 
neuromuscular studies showed that rocuronium had minimal effects on 
these variables with the dose of 2-3 ED 95. 
 
The autonomic margin of safety for vagal block (3.0-5.0) is about 
10 times less than that of vecuronium. In equipotent doses (2xED 95)   the 
administration of rocuronium was associated with small increase in heart 
rate of 7% (not statistically significant). However, there was increase in 
cardiac index of about 11 % (statistically significant) There was little 
change in MAP. 
 
Rocuronium causes increase in heart rate of over 30% of baseline in 
some patients .While the etiology of tachycardia is believed to be 
multifactorial, pain on injection or vagal blockade may contribute to 
tachycardia. Rocuronium is more likely than vecuronium less likely than 
pancuronium to cause tachycardia. 
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HISTAMINE RELEASE 
 
 
Rocuronium may cause histamine release. In a study of histamine 
release, 1 of 88 (1.1 %) patients receiving rocuronium has clinically 
significant concentration of histamine. In pre marketing clinical trials, 
rocuronium administration was accompanied by clinical signs of histamine 
release (eg, flushing, rash or bronchospasm) in 9 of 1137 (0.8%) patients. 
No clinical evidence of histamine release was observed in 45 patients 
enrolled in one study designed to provoke mine release by the rapid 
injection on rocuronium. No significant mine release with the dose of 
rocuronium up to 3xED95. 
 
CUMULATION 
 
 
Lack of cumulation has also been demonstrated by the absence of 
significant change in the dosage of rocuronium required to maintain stable 
relaxation with infusion lasting for over 2 hrs. 
 
VERSIBILITY AND POSTOPERATIVE CURARIZATION 
 
 
When adequate spontaneous recovery (an average of >TI of 25%) 
has occurred, the neuromuscular block induced with rocuronium can be 
antagonized by edrophonium or neostigmine. 
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APHYLACTIC/ANAPHYLACTOID REACTION 
 
 
No such anaphylactic/anaphylactoid reactions has so far been 
reported following administration of rocuronium. 
 
CENTRAL NERVOUS SYSTEM 
 
 
It has no effect as it does not cross the blood brain barrier. No effect 
on intracranial pressure. 
 
INTRAOCULAR PRESSURE 
 
 
It produces minimal change in intraocular pressure and appears to 
be safe for use in rapid sequence induction of anaesthesia for penetrating 
eye injuries. 
 
CENTAL TRANSFER 
 
 
Rocuronium does not cross placenta in significant amounts. 
 
 
PSEUDOCHOLINE ESTERASE INHIBITION 
 
 
This may result in the prolongation of action of drugs that dependent 
on cholinesterase for their metabolism like succinyl choline and 
mivacurium. The anticholinesterase activity of rocuronium is less 
than that of vecuronium. 
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SIDE/ADVERSE EFFECTS 
 
 
Pain on injection15- especially when the patient has not been 
completely lost consciousness and when propofol is used as an inducing 
agent in RSI. Hiccups, nausea, vomiting, aspiration,hypertension, 
hypotension, arrhythmias, bronchospasm, pruritus, rhonchi, skin rash, 
swelling at the injection site, tachycardia, wheezing.16,17 
PRESENTATION 
 
 
As a clear, colourless solution containg 10 mg/ml of rocuronium 
bromide. It is available in 5 ml and 10 ml vials. 
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PHARMACOLOGY OF EPHEDRINE 
 
 
 
 
 
Ephedrine is a synthetic non catecholamine.18,19 
 
It is an indirectly acting sympathomimetic drug. It is derived from 
Beta Phenylethlamine.18,19 
Ephedrine has OH group at the beta carbon of Beta 
Phenylethylamine. It does not cross the Blood Brain Barrier. 
 
MECHANISM OF ACTION : 
 
 
It acts by evoking the release of the endogenous neurotransmitter 
norepinephrine from Post-ganglionic sympathetic nerve endings.21 
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Denervation (or) depletion of neurotransmitter, as with repeated 
does of a sympathomimetic, blunts the pharmacologic responses normally 
evoked by the drug. 
 
It acts on  and  receptors 
 
CLINICAL EFFECTS : 
 
 
Cardiovascular System : 
 
 
Increases Heart rate and Cardiac output.22 
 
Increases Peripheral Vascular resistance and Mean arterial pressure. 
Uterine blood flow is not greatly altered when Ephedrine is administered. 
 
Repeated does of Ephedrine produces a  less  intense  response than 
the first dose. This Phenomenon known as tachyphylaxis22 which 
represents a persistent blockade of adrenergic receptors by the  previously 
administered Ephedrine. 
 
DOSAGE AND ROUTES OF ADMINISTRATION : 
 
 
Orally administered for decongesant effect. 
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Intravenous does 10 to 25 mg IV for adults23 
 
Ephedrine 0.5 mg/kg IM has an entiemetic effect similar to that of 
droperidol but with less sedation. 
Intra muscular and subcutaneous dose 25 to 50 mg 
 
USES: 
It is used as a pressor agent particularly after spinal hypotension20,23 
In Strokes – Adams syndrome with complete heart block it has a 
 
role similar to epinephrine 
 
 
Used as a central nervous stimulant in narcolepsy and depression 
It is also used in mayasthenia gravis 
Orally used as nasal decongestant20 
 
SIDE EFFECTS: 
 
 
With large doses headache,vertigo,tachycardia,palpitation and 
swetting can occur.19,21 
Urinary retention can occur in larger doses19 
Prolonged drug abuse with ephedrine sulphate injection can lead to 
symptoms similar to paranoid schizophrenia.19 
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DRUG INTERACTIONS: 
 
 
Concurrent use of ephedrine with general anaesthetics cyclopropane 
, halogenated compounds and digitalis can cause cardiac arrhythmias as 
these medications can sensitize the myocardium to the effects of ephedrine 
sulphate. 
 
Can block the effects of antihypertensives. 
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REVIEW OF LITERATURE 
 
1. Hernan R. Munoz, Alenjandro G. Gonzale etal., in 199724, 
compared the effects of a single dose of Ephedrine, given at the moment 
of induction, on the onset time of rocuronium and on blood pressure and 
heart rate with placebo. 
 
Patients were randomly assigned to receive either Ephedrine 70 
mg/kg (or) Saline 5ml (Group II - n=30) before thiopentone.  Rocuronium 
0.6 mg/kg was administered and tracheal intubation performed. 
 
Heart rate and blood pressure was measured prior to and 1, 3, and 
 
5 min after tracheal intubation. They found that the onset time of 
Rocuronium was 72 + 19S in group receiving Ephedrine and 98 + 31 in 
group receiving placebo. 
 
They also concluded that intubating conditions was either good (or) 
excellent and haemodynamic profile was similar in both groups and no 
patient presented arrythmias during study. 
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2. Peter szmuk, Tibriu Ezri, et al.25,26, compared the onset of 
action of Rocuronium when pretreated with either Esmolol, ephedrine and 
Placebo. 
 
ASA Physical status I & II patients aged 18-60 yrs. posted for 
General surgery and ENT procedures were assigned randomly into three 
groups. 
 
One group received 70 mg/kg of Ephedrine (Group n=20), second 
group received Esmolol 0.5 mg/kg (Group ES : n=20) and third group 
received saline placebo (Group n=20) is administered with fentanyl 3 
mg/kg 1.v and study drug followed 30S later by thiopentone 4mg/kg 
followed by rocuronium at 0.6 mg/kg. Neuromuscular function was 
assessed by stimulation of ulnar nerve at wrist with monitoring Train of 
four. 
 
Onset time of vecuronium was defined as the time from the end of 
its injection to disappearance of all found twitches of the train of four. They 
found that the onset time of Rocuronium was 43 + 6 seconds in group 
receiving placebo 64 + 6 seconds in groups receiving Esmolol and 118 + 
11 seconds in group receiving Ephedrine no significant changes were 
noted among the group with regard to heart rate and blood 
pressure. 
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3. M.D. Gopalakrishnan,27 H.M. Krishna in 2007  U.K.  Shenoy  
compared  the  effect  of  Pre-treatment with Ephedrine 75,  100, 
150 mg/kg and saline on intubating conditions and hemodynamics  
during rapid tracheal intubation using propofol and rocuronium. 
 
In this study one hundred adult  patients were randomized into   one 
of the four groups PE 75, PE 100, PE 150 and saline (control). Groups 
were pretreated with fentanyl 2mg/kg and I.V. Ephedrine 75, 100, 150 
mg/kg (or) saline respectively. 
 
1 min before rapid tracheal intubation using propofol 2.5 mg/kg and 
rocuronium 0.6 mg/kg. Intubating conditions were assessed. Heart rate and 
Mean arterial pressure were recorded before induction post induction and 
every minute for 5 min. Onset of action of Rocuroniun  was assessed by 
time for disappearance of all four twitches of TOF. 
 
In the studies they found that Ephedrine in the dosage of either 75 
or 100 mg/kg given before rapid tracheal intubation with propofol 2.5 and 
Rocuronium 0.6 mg/kg improved intubating conditions and these was no 
clinically significant difference in Heart rate and mean arterial Pressure 
among groups. 
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4. Leykin Y., Pellis, et al.,28 (2005) compared the effects of 
Ephedrine on intubating conditions following priming with rocuronium. 
 
In this study four groups of randomly allocated Patients (n=31) ASA 
I-II were induced with propofol 2.5 mg/kg. Groups I & II were primed with 
0.04 mg/kg of Rocuronium followed by 3 min priming interval. Intubation 
was performed at 30S. 
 
In groups III and IV same sequence was repeated without priming 
with Rocuronium. 
 
In groups I and II Ephedrine (210 mg / kg) was injected before 
propofol. In group III, IV equal volume of normal saline was injected. Jaw 
relaxation, vocal cord position and diaphragmatic response were used to 
assess intubating condition. 
 
They found that Ephedrine in Combination with propofol 
significantly improved clinical intubating conditions at 30S following 
priming with rocuronium compared with priming with Ephedrine  without 
priming with rocuronium. 
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5. KYO S. Klim,29 MIA Cheong et al (2002) compared the 
effect of Ephedrine on Vecuronium. In this study three groups of randomly 
allocated Patients (n=120) ASA II were divided to receive either Ephedrine 
(30,70, (or) 110 mg/kg (or) saline. 
 
Induced with prpofol and neuromuscular black was monitored by 
Train of four. They found that Both Ephedrine 70 and 110 mg/kg improved 
intubating conditions at 2 min after Vecuronium. However, 110 mg/kg was 
associated with adverse hemodynamic effects. They concluded that 
Ephedrine 70 mg/kg given before the induction of anaesthesia improved 
tracheal intubating conditions at 2 min after Vecuronium by increasing 
cardiac output without significant adverse hemodynamic effects. 
 
6. C.H. Tan, M.K. Onisong et al.30, compared the influence of 
induction technique on intubating conditions 1 min. after rocuronium 
administration with poropofol ephedrine combination and propofol. In this 
study 100 ASA I (or) 2 patients aged 18-65 were randomly allocated to 
receive either propofol 2.5 mg/kg and Ephedrine 15g in combination (or) 
propofol 2.5 mg/kg alone followed by rocuronium 0.6 mg/kg. Intubating 
conditions were assessed with criteria of cooper et al. 
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The study found that intubating conditions were clinically 
acceptable in all patients, but the proportion of Excellent intubating 
conditions was significantly higher in propofol - Ephedrine group. 
 
7. D.W. Han, D.H.Chun, T.D.Kweon S.Shin31 studied the 
significance of “injection timing of Ephedrine to reduce the  onset time  of 
rocuronium Anaesthesia 2008;63:856 – 860. 
 
In this study 75 adult male patients were used . They were randomly 
separated into three groups ,denoted to the time in which ephedrine was 
given. The early group ephedrine 70microgram/kg given 4min before 
rocuronium.Next group saline given at 4 min.In the last group ephedrine 
given at 30 seconds. 
 
The study found that the onset of action of rocuronium was 
significantly shorter in Early group. 
 
8. Smith and RSD Saad,32 in 1998, compared the onset of action 
and the intubating conditions after rocuronium O.6mg/kg and vecuronium 
0.1mg/kg. The time of intubation was determined  by  clinical judgment. 
alone like the ease of ventilation, jaw relaxation and upper airway tone. 
They concluded that time to laryngoscopy and completion of intubation 
were markedly shorter in the rocuronim group. 
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Rocuronium group also resulted in significantly better intubation 
conditions. There were no significant differences between the groups in 
hemodynamic response to laryngoscopy or in oxygen saturation before  or 
after tracheal intubation. 
 
9. Benoit Plaud, Bertrant Debaene et a133., in 2001, measured 
the evoked response to train-of-four stimulation in twelve patients at the 
thumb,eyelid and superciliary arch after 0. 5 mg/kg rocuronium during 
propofol - fentanyl - nitrous oxide anaesthesia. In 12 other patients 
laryngeal adductor neuromuscular blockade was assessed via the cuff of 
tracheal tube and compared with the adductor pollicis and the  corrugators 
supercilii after 0. 6 mg/kg rocuronium. They found that with the dose of 
0.6 mg/kg of rocuronium, maximum blockade was similar at the 
corrugators supercilii and the laryngeal adductors. They concluded that 
muscles around the eye vary in their response to rocuronium. The response 
of the corrugators supercilii reflects blockade of laryngeal adductor 
muscles. However the eyelid (orbicularis oculi) and thumb (adductor 
pollicis) have similar sensitivity 
 
10. Mistelman, C. Plaud B et34 al., in 1994, compared the 
neuromuscular blocking effect of 0.5 mg/kg rocuronium at the adductor 
pollicis and laryngeal adductor muscles. They demonstrated that 
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rocuronium produces more rapid but less intense vocal cord 
neuromuscular block than at the adductor pollicis. The onset time at the 
vocal cords was markedly shorter for rocuronium when compared to 
vecuronium, atracurium and succinylcholine. They recorded the onset time 
of 1. 4±0. 1 min at larynx with maximum block of 77±5% and 2. 
5±lminutes at adductor pollicis with maximum block of 98±1 %. 
 
11. Prein TH, Zahn P et al.,35 in 1994, studied the ED 95 dose  of 
rocuronium bromide, the tracheal intubating conditions and the time 
course of action. They concluded that the ED 95 dose of rocuronium 
bromide was 0.3mg/kg and the duration of action was 20 minutes. 
 
12. Cooper R. Mirakhur et al.,36 in 1992, compared the intubating 
conditions with rocuronium bromide 0.6 mg/kg and succinylcholine 1 
mg/kg at 60 seconds. They used a scale to assess the intubating condition 
which took into consideration the ease of laryngoscopy, position of the 
vocal cords during scopy and the response to tracheal intubation. 14/20 
patients in rocuronium group had excellent intubating conditions. 4/20 and 
2/20 had good to fair and  poor  intubating conditions respectively. 
Whereas 19/20 patients in succinylcholine group had excellent intubating 
conditions and 1 patient had good conditions. 
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13. K. F. Cheong and W. H. Wong15 in 2000, assessed the 
incidence of pain on injection to rocuronium and evaluated if pretreatment 
with lignocaine IV reduced it in 90 patients. 37% of  patients in ligocaine 
10mg group, 7% in lignocaine 30mg group  and 77% in control group who 
received saline pretreatment had pain. They concluded that lignocaine 
pretreatment decreased the incidence and severity of pain on injection of 
rocuronium. 
 
14. M. Rose and M. Fischer16 in 2001, identified 24 patients who 
met the clinical and laboratory criteria for anaphylaxis to rocuronium. 
They suggested that rocuronium is intermediate in its potency to cause 
allergy in known relaxant reactors compared with low risk agents like 
pancuronium, vecuronium and high risk agents like alcuronium and 
succinylcholine. 
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MATERIALS AND METHODS 
 
It was a prospective, Randomized, Double blinded(subject), Case 
control study conducted in the Institute of Anaesthesiology and Critical 
Care, Madras medical college and Government General Hospital, Chennai 
 
INCLUSION CRITERIA: 
 
 
 MALES AND FEMALES 
 
 ASA PHYSICAL STATUS 1,2,3 
 
 AGE 15 YEARS AND OLDER 
 
 ELECTIVE PATIENTS GIVEN GENERAL ANESTHESIA 
 
 PATIENT WHO HAD GIVEN INFORMED CONSENT 
 
EXCLUSION CRITERIA: 
 
 NOT SATISFYING INCLUSION CRITERIA 
 
 EMERGENCY SURGERIES UNDER GA 
 
 PATIENTS WITH NEUROMUSCULAR 
DISORDERS,CARDIOVASCULAR DISEASE. 
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 HEPATIC OR RENAL DISEASE 
 
 PATIENTS WITH DIFFICULT AIRWAY 
 
 INTAKE OF DRUGS KNOWN TO INTERACT WITH 
MEUROMUSCULAR JUNCTION OR EPHEDRINE 
 INCREASED RISK OF PULMONARY ASPIRATION 
 
MATERIALS : 
 
 
• INJECTION EPHEDRINE 70 MICROGRAM /KG 
 
 
• DRUGS – 
FENTANYL,GLYCOPYRROLATE,THIOPENTONE,XYLOCARD,ROCURO 
NIUM BROMIDE,NORMAL SALINE,EMERGENCY DRUGS. 
 
• MACINTOSH LARYNGOSCOPE WITH 3,4 BLADES 
 
 
• ENDOTRACHEAL TUBES OF VARIOUS SIZES 
 
 
• MONITORS‐ ECG,NIBP,SPO2,NEUROMUSCULAR MONITOR 
 
 
PRIMARY OUTCOME MEASURES: 
 
 ONSET TIME OF ROCURONIUM AFTER TEST DRUG AND 
PLACEBO 
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SECONDARY OUTCOME MEASURES: 
 
 
 INTUBATING CONDITIONS AFTER TEST DRUG AND 
PLACEBO 
 
 HEMODYNAMIC VARIABLES 
 
METHODOLOGY 
 
 
PREMEDICATION: INJ.MIDAZOLAM 2 MG IV, 
INJ.GLYCOPYROLLATE 0.2 MG 
 
10 MIN BEFORE TEST DRUG 

TEST DRUG IS GIVEN 1 MIN BEFORE INDUCTION 

JUST BEFORE INDUCTION INJ.XYLOCARD 
1.5 MG/KG IV GIVEN 

INDUCTION: INJ.FENTANYL 2 G/KG IV , 
INJ.THIOPENTONE 5 MG/KG IV 

1 MIN AFTER INDUCTION INJ.ROCURONIUM 0.6 MG / 
KG IV GIVEN 

ONSET TIME OF ROCURONIUM IS TAKEN FROM THE TIME OF 
INJECTION OF DRUG TO THE DISAPPEARANCE OF T1 IN TOF 
AND DISAPPEARANCE OF SINGLE TWITCH STIMULATION 
PATIENT IS THEN INTUBATED AND CORMACK AND EHANE 
GRADE AND POGO SCORE ASSESSED 
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EPHEDRINE DOSE – 70 g/kg 
 
 
PLACEBO- SALINE 5ml 
 
 
MEASUREMENTS 
 
 
 Ulnar nerve was monitored using nerve stimulator. 
 
Supramaximal stimulus kept during induction. 
 
 
  Disappearance of single twitch stimulation and disappearance of 
T1 of TOF is the goal. 
 
 Stop clock was started from drug injection until disappearance of 
single twitch stimulation and disappearance of T1 of TOF. 
 
Blood pressure and heart rate was measured 
 
 
 Baseline 
 
 After pre-medication, 
 
 After test drug administration, 
 
 Induction 
 
 During intubation 
 
 1,3 min after intubation. 
 
 CORMACK LEHANNE GRADING AND POGO SCORE 
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CORMACK AND LEHANE GRADING SYSTEM38-40: 
 
Entire vocal cord visualized - Grade I 
 
 
Posterior part of vocal cords seen - Grade IIa 
 
 
Arytenoids only seen - Grade IIb 
 
 
Epiglottis only seen (liftable) - Grade IIIa 
Tip of epiglottis only seen (adherent) - Grade IIIb 
No glottis structure seen - Grade IV 
POGO SCORE40-42: 
It represents the percentage of glottis opening seen, defined by  the 
linear space from the anterior commisure to the interarytenoid notch. 
 
A score of 100% is a full view of the glottis from the anterior 
commisure to the interarytenoid notch . A pogo score of 0% means that 
even the interarytenoid notch is not seen . 
 
Thus, if only the lower third of the vocal cords and the arytenoids 
are visible a score of 33%is given. 
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This may be a better classification of the glottis view than the 
cormack and lehane’s class I and II , as it offers nothing in between   these 
two grades of glottic view. 
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OBSERVATION AND RESULTS 
 
This prospective, randomized, single blind (subject), case 
controlled study compared the Effects of intravenous Ephedrine on the 
onset time of rocuronium bromide and intubating conditions measured  by 
haemodynamic alterations and pogo score. 
 
PRIMARY OUTCOME MEASURES: 
 
 
 ONSET TIME OF ROCURONIUM AFTER TEST DRUG AND 
PLACEBO 
 
SECONDARY OUTCOME MEASURES: 
 
 
INTUBATING CONDITIONS USING 
 
 
 HEMODYNAMIC VARIABLES 
 
 POGO SCORE AND CORMACK AND LEHANE GRADING 
All data were collected and tabulated. 
DEMOGRAPHIC VARIABLES: 
 
 
60 patients were randomly selected and included in this study. 
Thirty patients were randomly assigned to receive PLACEBO of 5ml 
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saline (group A) and thirty patients received the test drug of 
70microgram/kg EPHEDRINE (group B). Mean age, sex  distribution and 
weight of the patients in both the group were compared and there was no 
significant difference between the groups. 
 
Comparison between the onset time of rocuronium  in  patients 
who received placebo and test drug ephedrine is tabulated as follows 
 
T-Test 
 
 
 
 GROUP 
PLACEBO 
n=30 
EPHEDRINE 
n=30 
 
Mean SD Mean SD P value 
ONSET 
TIME 
 
60.23 
 
17.154 
 
50.70 
 
15.454 
 
0.027 
 
POGO 
SCORE 
 
 
74.40 
 
 
26.94 
 
 
90.40 
 
 
15.67 
 
 
0.013 
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CORMACK LEHANE GRADING 
 
 
Chi square test: 
 
 
 
  
CL grade I 
 
CL grade II 
 
PLACEBO 
 
14 
 
16 
 
EPHEDRINE 
 
25 
 
5 
 
 
 
Onset time of rocuronium bromide after placebo of  5ml  saline was 
studied in thirty patients and the mean time of onset was found to be 
60.23  seconds.  Standard  deviation  was  calculated and found to be 
17.154 
 
Onset time of rocuronium after test drug of 70 microgram/kg of 
Ephedrine was studied in thirty patients and the mean time for onset of 
action was found to be 50.70 seconds with standard deviation of 15.454 
 
 
 
Both the results were statistically analysed with T-Test and  P value 
was found to be 0.027 
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Intubating conditions were assessed with POGO SCORE AND 
CARMAK LEHANE grading 
 
Using POGO score intubating conditions were graded and mean 
percentage calculated for placebo as 74.40 with standard deviation 26.94 
when given Ephedrine the mean percentage was found to be 90.40 with 
Standard deviation of 15.67. 
 
Here the intubating conditions were better in the Ephedrine group 
with a P value of 0.013 
 
P value is 0.01 which is statistically significant and the ephedrine 
group is associated with better intubating conditions 
 
The other secondary outcome studied is the  hemodynamic 
changes ,which includes Heart rate and Blood pressure 
 
Heart rate and Blood pressure is noted with baseline value , after 
giving premedication ,after giving test drug , after induction, intubation 
,one minute and three minute after intubation. 
 
 
In the study it was found that Heart rate and Blood pressure was 
not altered significantly. 
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HEART RATE 
GROUP 
PLACEBO EPHEDRINE P 
 
VALUE MEAN SD MEAN SD 
Baseline 89.07 18.398 88.53 16.598 0.907 
Premedication 92.33 18.421 92.97 14.041 0.881 
Test drug 93.13 18.822 97.43 16.569 0.352 
Induction 98.07 18.097 103.67 12.928 0.173 
Intubation 99.53 15.462 116.30 11.490 0.059 
1 min after intubation 105.77 19.098 112.20 15.298 0.155 
3 min after intubation 100.60 17.399 106.50 13.495 0.148 
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BLOOD PRESSURE 
GROUP 
PLACEBO EPHEDRINE  
PVALUE 
MEAN SD MEAN SD 
Baseline systolic 131.37 15.270 126.63 12.931 0.210 
Baseline diastolic 86.97 7.613 86.23 9.971 0.750 
Premedication 
systolic 
127.90 14.928 123.37 13.087 0.216 
Premedication 
diastolic 
84.77 8.59 80.93 7.629 0.073 
Test drug systolic 123.23 15.710 126.73 14.137 0.368 
Test drug diastolic 83.37 8.096 85.80 11.613 0.350 
Induction systolic 103.93 17.382 113.47 11.221 0.148 
Induction diastolic 75.73 13.465 81.33 12.732 0.103 
Intubation systolic 115.97 18.299 121.70 10.107 0.138 
Intubation diastolic 81.10 14.719 87.43 16.827 0.126 
1 min after intubation 
systolic 
136.57 28.803 127.83 19.298 0.173 
1 min after intubation 
diastolic 
92.60 19.344 86.57 13.056 0.162 
3 min after intubation 
systolic 
129.33 18.318 123.07 12.649 0.129 
3 min after intubation 
diastolic 
85.23 11.422 82.03 11.33 0.281 
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DISCUSSION 
 
The cardinal requirements of general anaesthesia are 
 
 
1. Loss of all sensation 
 
 
2. Sleep(unconsciousness) 
 
 
3. Muscle relaxation and 
 
 
4. Abolition of reflexes 
 
 
In the modern practice of balanced anaesthesia , these modalities are 
achieved by combination of drugs,each drug for a specific purpose. 
 
In high risk patients who are prone to aspiration, rapid sequence 
induction is the preferred technique of induction. Succinylcholine 
continues to be the relaxant of choice where there is a need for rapid 
tracheal intubation as it consistently provides muscle relaxation within 
60 – 90 seconds. When Succinylcholine is contraindicated in some patients 
the onset of action of non-depolarizing drugs can be accelerated by various 
methods. 
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The fast and reliable onset time of suxamethonium is the gold 
standard against which all other muscle relaxants are compared  but  some 
side effects preclude its use in all patients.43 
This has led to a long standing interest in decreasing the onset 
time of non-depolarizing Neuromuscular blocking drugs,resulting in the 
development of faster drugs.44 
Silveverman SM, Culling RD demonstrated that the timing 
principle for rapid sequence induction is a reliable alternative in cases 
where suxamethonium is contraindicated 45 
Mohamed Naguid has demonstrated that priming a rocuronium 
block with rocuronium resulted in a neuromuscular block comparable to 
that of suxamethonium in both the onset of action and intubating 
conditions. 46 
These alternative Timing and Priming principles reduce the 
onset time of these drugs but can also lead to adverse effect such as 
development of muscle weakness, difficulty in breathing , loss of the 
protective reflexes of the airway and pulmonary aspiration15,16 before the 
induction of anaesthesia (9-11 ) or increased duration of neuromuscular 
blockade47 
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PRETREATMENT WITH EPHEDRINE 
 
The use of ephedrine during the induction of general anaesthesia has 
been described to accelerate the onset of action of rocuronium and improve 
intubating condition.24-31 
Studies using induction agents that maintain cardiac output and 
arterial blood pressure like ketamine,etomidate have suggested that the use 
of these drugs was associated with faster onset of action and better 
intubating conditions .26,27 
Ephedrine by increasing the cardiac output and tissue perfusion and 
resulting in faster delivery of rocuronium to the laryngeal and 
diaphragmatic muscles might have shorten the onset of action of 
rocuronium and intubating conditions27 
In our study thiopentone was used as induction agent. In various 
studies propofol was also used as induction agent.37 
Various doses of Ephedrine were used for this purpose 
 
Gopalakrishnan M.D , U.K. Shenoy in  their  study  used ephedrine 
in the dose of 75, 100, 150 microgram /kg27 
Hernan R.munoz in their study used 70, 210, 260 microgram/kg 
 
of ephedrine24 
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In our study we used 70microgram/kg of ephedrine and compared it 
with Saline. We decided to use the smallest dose (70microgram/kg) to 
minimize the possibility of adverse effects. 
Audibert G, Donati F48 onset of Neuro Muscular block after 
tourniquet inflation.Comparison of suxamethonium and vecuronium 
British journal of anaesthesia 1996;75:436 – 440 in their study showed that 
the effects of cardiac output and circulation time may be 
considerably greater for fast acting muscle relaxants such as 
suxamethonium and rocuronium than intermediate acting muscle relaxants 
including mivacurium and vecuronium.49 
In our study rocuronium was chosen since it is the non- depolarizing 
Neuromuscular blocking drug in clinical use with the  fastest onset time.36 
In our study we used 70microgram/kg of ephedrine one minute 
before induction with inj thiopentone 5mg/kg and one minute after 
induction inj rocuronium 0.6mg/kg I.V was given.In few studies  propofol 
is used in combination with ephedrine as induction agent.37 
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TIME OF ONSET OF ACTION 
 
 
M.D. Gopalakrishna, U.K.Shenoy etal,27 British journal of 
anaesthesia 2007;99:191-194 
 
In their study used ephedrine at doses of 
75,100,150microgram/kg and saline, used Train of four(TOF) 
ratio monitoring in response to ulnar nerve stimulation . The 
lack of agreement between the blockade characteristics at the 
laryngeal muscles and the adductor pollicis is well 
demonstrated in the literature50-53 
However as the site of monitoring was the same in all four groups , the 
results can still be compared for the difference in onset of 
Nero muscular block. 
 
In our study we used ezteemII Neuromuscular monitor was used. Onset 
time of Rocuronium is taken from the time of injection of 
drug to the disappearance of 
 
1. T1 in Train of four 
 
 
2. Dissapeaarance of single twitch stimulation 
60  
We found that the mean time for onset of action of rocuronium in 
placebo group to be 60.23 seconds and ephedrine pretreated 
group onset of action was found to be 50.70 seconds with P 
value of 0.02 
 
Complete abolition of single twitch was observed in 27 patients in each 
group. In the remaining six patients 95% twitch depression 
was achieved. 
 
 
 
SIGNIFICANCE OF TIMING OF INJECTION OF 
 
EPHEDRINE: D.W. Han, D.H.Chun, T.D.Kweon S.Shin31 studied the 
significance of “injection timing of Ephedrine to reduce the  onset time  of 
rocuronium Anaesthesia 2008;63:856 – 860. 
 
In this study 75 adult male patients were used . They were randomly 
separated into three groups ,denoted to the time in which ephedrine was 
given. The early group ephedrine 70microgram/kg given 4min before 
rocuronium.Next group saline given at 4 min.In the last group ephedrine 
given at 30 seconds. 
The study found that the onset of action of rocuronium was 
significantly shorter in Early group. 
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In our study Ephedrine was given one minute before induction and 
rocuronium was given one minute after induction which give around three 
to four minutes for ephedrine to get its peak circulatory effects . 
 
INTUBATING CONDITIONS 
 
 
Intubating conditions depend on many factors the most important of 
which are the degree of relaxation of the muscle involved,the depth of 
anaesthesia,the anatomy of the upper airway and the skill of the 
anaesthetist.The superior intubating conditions associated with 
suxamethonium not because of its rapid onset but may because it has a 
greater potency at the laryngeal muscles than non-depolarizing blocking 
drugs43 .However Gopalakrishna M.D, U.K.Shenoy  etal27,  British journal 
of anaesthesia 2007;99:191-194 assessed the intubating conditions as per 
the intubation scoring system of the consensus conference on good clinical 
research practice in pharmacodynamic studies of Neuromuscular block of 
Copenhagen consensus.52 and found that pretreatment with 75 and 100 
microgram/kg ephedrine group had significantly better intubating 
conditions . 
 
In our study we used POGO score and cormack Lehane 
classification to assess the intubating conditions. 
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We found that the mean POGO score for Placebo group was 
found to be 74.40 and for Ephedrine group to be 90.40 proving better 
intubating condition in ephedrine group. 
 
HEMODYNAMIC CHANGES 
 
 
1. Smith and R.S.D  Saad 32demonstrated that  rocuronium resulted  in 
significantly better intubating conditions compared with 
vecuronium but with no significant reduction in the hemodynamic 
response to intubation 
 
2. Hernan R.Munoz, Alenjandro etal24, in international anaesthesia 
society Anaesthesia anal 1997;85:437 – 440 in their study found that 
pretreatment with 70microgram/kg ephedrine found that there was 
no significant hemodynamic changes in group treated with placebo 
and ephedrine 
 
In our study we considered a 20% change in hemodynamic variables 
from baseline was regarded as clinically significant. We found that the 
Baseline Heart rate and Blood pressure were comparable  between groups. 
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There was a significant increase in the heart rate and systolic and 
diastolic blood pressure when compared to Placebo group at most of the 
time intervals of the study period. But it is not raised at statistically 
significant levels 
 
INCIDENCE OF ADVERSE EFECTS 
 
 
There are reports of various adverse effects of rocuronium  bromide 
like pain on injection,hypotention ,wheel response,flushing , 
bronchospasm and anaphylaxis are possible after the administration of 
rocuronium(). In our study we used injection Xylocard15 before 
rocuronium administration and there was no significant adverse effect to 
rocuronium. 
 
Also in our study we did not find  any adverse effect of greater than 
20% raise in Heart rate and Bloodpressure and arrhythmias in any  of our 
patients. 
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SUMMARY 
 
In our study, the effect of intravenous “Ephedrine” on the onset time 
and intubating conditions of rocuronium bromide was compared with 
“Placebo”. 
 
All the patients in Ephedrine group were pretreated with  ephedrine 
70microgram/kg prior to induction and rocuronium 0.6mg/kg was given . 
All the patients in “Placebo” group were given 5ml Saline prior to 
induction . 
 
Onset of action is determined by abolition T1 in TOF and absence 
of single twitch stimulation in Neuro muscular monitor . 
 
The onset of action of Rocuronium was significantly shorter in 
“Ephedrine”group when compared to “Placebo” group. 
 
Ephedrine group provided better intubating conditions when 
compared with Placebo group 
 
There was no clinically significant difference between the two 
groups with respect to heart rate and blood pressure changes.There was no 
significant incidence of adverse effects in both groups 
65  
CONCLUSION 
 
It may be concluded from this study that “Ephedrine given at 
the dose of 70microgram/kg significantly shortens the onset time of 
Rocuronium bromide and provides better intubating conditions with 
minimal haemodynamic changes.” 
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PROFORMA 
 
 
NAME: AGE: SEX: I.P. NO. 
 
DIAGNOSIS: WT: MMS CLASS: 
SURGERY PERFORMED:  TEST DRUG: 
1. HEMODYNAMICS: 
 
 
 HR BP 
BASELINE   
AFTER PREMEDICATION   
AFTER TEST DRUG   
AFTER INDUCTION   
AFTER INTUBATION   
1 MIN   
3 MIN   
 
 
2. TIME: 
 
 
TEST DRUG SEC 
TIME FOR DISAPPEARANCE OF TI IN TOF OR STS SEC 
 
3. INTUBATING CONDITIONS: 
 
 CORMACK LEHANNE GRADE – 
 
 POGO SCORE – 
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INFORMATION ON THE STUDY 
 
EFFECT OF I.V EPHEDRINE ON THE ONSET TIME AND INTUBATING 
CONDITIONS OF ROCURON1UIVI BROMIDE. 
 
 
Rocuronium is used to administer General Anaesthesia. Ephedrine fastens the onset 
of action of rocuronium. This also helps us to reduce the dose of Rocuronium and hence 
prolonged musule relaxant action after minor surgical procedures. The time  Interval 
between the patient becoming unconscious and Intubation is decreased as rocuronium 'onset 
of action is fasterned. This helps in prevention of Aspiration. Since onset of action is  
comparable with Suxamethonium. It can be used as an alternative  where Suxamethonium 
is Contra indicated. The use of Ephedrine can cause untoward increase in Heart rate and 
blood pressure. In case of such occurance it will be  continuously monitored and treated by 
the doctor  appropriately.  No  major  complications causing morbidity / mortality are so far 
reported. Knowing  this information, I consent to whole heartedly participate in the above 
study. 
 
 
 
Name: Patient's Signature 
 
Thumb Impression: 
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PATIENT CONSENT FORM 
 
STUDY TITLE : Prospective randomized controlled study of iv ephedrine on the 
onset time and intubating conditions of rocuronium bromide. 
 
STUDY CENTRE : Department of Anaesthasiology, Madras Medical College. 
PARTICIPANT NAME : AGE : SEX: 
I.P.NO : 
I confirm that 1 have understood the purpose of procedure for the above 
study. I have the opportunity to ask the question and all my questions and doubts 
have been answered to my satisfaction. 
 
I have been explained about the possible complications that may occur 
during this study like increase in heart rate and blood pressure and in case of such 
occurrence it will be continuously monitored and treated accordingly .1 have been 
informed that no other major complication has been reported so far with the use of 
ephedrine . 
 
I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving any reason, 
 
I understand that investigator, regulatory authorities and the ethics committee 
will not need my permission to look at my health records both in respect to the 
current study and any further research that may be conducted in relation to it, even if 
I withdraw from the study". I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from the study of iv 
ephedrine on the onset time and intubating conditions of rocuronium bromide 
 
1 hereby consent to participate in this 
 
 
 
Dale: Signature /Thumb impression of patient 
Place  Patient name : 
 
 
Signature of the investigator: Name of the investigator: 
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ONSET TIME 
Sl. No. name age sex weight mms drug hr_base hr_pre hr_test hr_ind hr_int hr_1min hr_3min bps_base bpd_base bps_pre bpd_pre bps_test bpd_test bps_ind bpd_ind 
1 SUBRAMANI 36 M 60 I 1 74 65 66 91 95 95 94 148 89 134 92 130 90 128 92 
2 SUSEELA 17 F 50 I 1 122 127 122 116 120 126 109 110 87 110 80 110 80 118 74 
3 ANANDHAN 32 M 50 I 1 86 79 82 94 108 113 110 144 95 140 90 130 88 100 70 
4 BHAVANI 19 F 50 I 1 125 121 120 124 110 108 112 120 80 120 83 110 80 113 81 
5 KANCHANA 28 F 50 I 1 110 133 130 121 122 138 126 140 80 130 80 130 74 100 80 
6 MANICKAMMAL 38 F 45 I 1 80 86 86 90 90 97 102 123 91 116 93 116 93 114 90 
7 MALLIGA 51 F 60 II 1 90 80 82 93 98 102 92 130 80 120 70 110 84 90 72 
8 USHARANI 50 F 60 I 1 66 82 80 74 70 75 62 172 100 168 98 160 90 99 69 
9 FATHIMA 23 F 70 I 1 86 106 122 116 110 124 110 130 80 120 80 110 86 90 60 
10 ANANDHI 42 F 55 I 1 81 86 84 81 83 80 96 124 86 124 87 120 84 110 80 
11 KASTHURI 55 F 50 II 1 102 98 95 94 90 96 90 132 87 149 96 149 96 90 61 
12 SRINIVASAN 30 M 50 I 1 88 98 102 116 106 130 114 124 93 133 87 133 80 100 73 
13 HABITHA BEEVI 45 F 50 I 1 101 96 97 110 114 115 113 128 89 128 90 120 80 90 60 
14 RESHMA 39 F 56 l 1 52 68 67 62 72 67 62 130 80 126 80 100 74 90 60 
15 KANNAN 30 M 65 ll 1 86 79 82 94 106 112 110 144 95 142 90 130 88 100 70 
16 KANNIYARAM 50 M 55 II 1 72 62 64 76 80 113 71 119 72 117 70 117 71 100 66 
17 KULANTHAI 44 M 66 ll 1 86 100 120 116 110 124 110 130 80 120 80 110 90 87 58 
18 MADHAN 42 M 60 ll 1 88 96 95 94 82 80 94 122 84 120 80 110 86 90 60 
19 KOLANJI 35 F 60 II 1 110 96 99 113 110 108 106 138 94 128 95 128 95 98 62 
20 VIJAYALAKSHMI 36 F 50 I 1 120 125 120 114 113 119 108 106 85 104 80 110 70 109 85 
21 DEVI 26 F 50 I 1 98 103 104 109 110 124 122 114 83 110 71 124 86 110 73 
22 LAKSHMI 37 F 45 I 1 75 93 96 102 108 108 111 131 98 130 97 130 90 146 111 
23 CHINNARAJI 37 F 70 I 1 106 105 108 103 100 117 113 153 97 156 91 156 91 144 88 
24 SARASWATHI 50 F 70 II 1 52 68 67 62 72 67 62 130 80 127 80 100 74 90 60 
25 RATHI 41 F 60 II 1 93 84 86 67 72 82 86 153 92 151 90 150 90 140 96 
26 GAYATRI 22 F 40 I 1 104 101 86 130 115 130 118 113 76 113 76 106 73 101 72 
27 KALAIVANI 30 F 56 l 1 74 66 66 91 94 94 92 144 88 132 90 128 88 126 90 
28 RAMESH 25 M 55 l 1 75 92 95 100 106 106 104 106 85 104 80 110 70 108 86 
29 RAVI KUMAR 25 M 50 II 1 90 92 88 93 110 117 114 150 103 135 97 130 90 127 93 
30 GANESH 54 M 80 II 1 80 83 83 96 110 106 105 130 80 130 70 130 70 130 80 
31 GEETHA 38 F 50 II 2 86 93 100 101 126 140 108 149 90 160 95 160 90 140 99 
32 SARASWATHY 23 F 40 I 2 106 116 108 120 135 126 118 120 80 130 84 140 92 100 70 
33 KUMUDHA 45 F 55 II 2 64 76 57 72 84 82 80 130 80 120 74 110 80 100 66 
34 PADMA 40 F 55 I 2 96 103 115 110 140 118 116 110 80 109 81 107 68 90 64 
35 MANJULA 30 F 50 I 2 84 76 94 98 130 102 110 130 80 120 70 130 80 100 76 
36 DHARANI 18 F 45 I 2 110 113 122 124 138 144 112 120 70 110 80 120 66 110 80 
37 RANI 23 F 55 I 2 67 78 89 90 112 123 90 110 90 119 90 130 80 109 89 
38 SUSEELA 47 F 60 II 2 90 95 102 110 120 108 110 140 80 134 94 140 98 140 110 
39 ARJUNAN 16 M 40 II 2 84 81 116 120 118 108 92 140 70 130 80 140 90 130 80 
40 PARVATHY 30 F 50 I 2 114 110 120 114 122 118 120 120 80 130 70 100 80 120 70 
41 RANI 20 F 45 I 2 64 76 84 98 98 97 95 112 71 130 80 120 76 140 100 
42 DEEPA 28 F 50 II 2 103 102 97 107 119 118 113 120 70 110 80 107 64 110 80 
43 NANDINI 24 F 55 I 2 101 96 113 120 122 129 111 127 90 131 90 140 88 120 92 
44 DHANALAKSHMI 26 F 52 I 2 110 107 112 109 114 96 124 135 91 133 90 132 89 130 94 
45 NALINA 31 F 50 I 2 121 119 128 130 130 104 103 152 97 130 81 130 80 140 90 
46 BHAVANI 16 F 50 I 2 87 96 113 114 111 120 133 152 90 149 91 148 103 148 102 
47 RAMANA 18 M 68 II 2 90 75 82 95 100 126 124 120 80 110 74 140 90 106 70 
48 CHINNATHAMBI 40 M 50 II 2 71 86 82 85 90 92 109 132 86 132 86 131 87 118 80 
49 LAKSHMI 38 F 65 II 2 80 84 86 97 96 92 75 130 84 110 82 120 76 100 66 
50 SUMATHY 20 F 40 I 2 101 106 92 94 101 115 114 126 84 120 80 114 76 127 82 
51 MANISHA 18 F 55 I 2 106 94 99 102 108 124 119 117 74 101 65 102 65 110 62 
52 MANJULA 23 F 45 II 2 84 114 102 109 120 130 120 100 80 100 76 110 80 90 70 
53 ARUN KUMAR 16 M 50 I 2 81 94 64 90 120 107 106 130 80 120 70 130 74 110 70 
54 NAGALINGAM 39 M 50 I 2 99 104 96 98 89 109 108 129 85 128 86 130 89 102 73 
55 VIJI 23 F 60 I 2 78 91 90 105 96 123 100 130 85 129 81 121 76 119 83 
56 KARTHICK 29 M 56 ll 2 83 74 92 97 128 100 108 128 78 118 70 130 78 98 74 
57 LAKSHMANAN 35 M 60 l 2 66 78 88 92 110 122 88 108 88 118 88 128 80 108 90 
58 DURAI 40 M 66 l 2 100 94 112 118 116 106 94 140 70 130 80 120 76 140 100 
59 MEENATCHI 35 F 70 l 2 64 76 84 98 98 97 95 112 71 130 80 140 90 130 80 
60 RAJAN 33 m 66 l 2 66 82 84 93 96 90 100 130 82 110 80 132 90 126 78 
bps_int bpd_int bps_1 bpd_1 bps_3 bpd_3 onset cl_grade pogo ip_no 
130 100 143 107 130 90 50 I 90 72410 
118 70 149 116 118 81 40 II 60 70969 
140 100 180 110 153 100 80 II 30 70970 
92 63 90 60 114 72 100 I 100 70073 
120 70 140 110 130 90 50 II 90 71678 
114 89 136 108 99 79 50 I 100 29286 
100 74 150 90 140 86 95 II 60 70536 
119 83 120 74 157 97 65 I 90 63510 
110 80 90 64 100 70 45 II 100 78533 
119 85 117 89 118 89 55 I 80 67540 
90 61 150 100 111 80 45 II 50 69739 
107 76 173 110 163 105 75 I 100 30410 
96 70 69 55 130 96 55 I 100 65828 
90 64 134 70 136 74 70 l 80 68114 
140 100 172 108 150 100 80 ll 80 71145 
110 66 155 93 144 89 65 I 100 67800 
108 76 166 110 162 105 75 II 80 70899 
110 80 90 64 100 70 45 l 100 64431 
99 60 120 66 110 64 80 I 100 46245 
127 100 120 94 120 74 40 I 100 71222 
110 66 124 91 110 83 50 II 30 57888 
93 78 100 76 110 70 54 II 40 66374 
140 90 176 124 125 92 40 II 50 68145 
90 55 140 70 145 75 78 I 90 67871 
126 85 159 99 140 90 40 I 100 68132 
147 102 159 100 135 82 45 II 70 70515 
128 100 140 106 130 90 80 ll 80 77567 
126 100 118 94 120 74 50 ll 80 66742 
120 90 167 110 140 100 60 II 60 70220 
160 100 150 110 140 90 50 II 50 61557 
190 110 180 100 140 107 35 II 80 76895 
100 80 120 70 90 60 31 I 100 77088 
120 74 110 80 120 70 58 I 100 70820 
140 100 113 81 113 80 40 I 90 68572 
150 110 126 92 120 84 39 I 100 74022 
140 110 120 80 110 70 70 I 100 72903 
150 99 114 80 120 70 40 I 100 66788 
130 80 120 74 110 80 32 II 50 73285 
120 70 110 80 120 74 100 I 100 70554 
110 80 140 90 108 70 45 I 100 72477 
114 75 114 77 113 76 34 I 100 73406 
125 80 125 87 93 67 35 I 100 74094 
131 86 145 94 143 99 55 I 90 73494 
140 109 129 94 145 109 25 I 100 72829 
140 96 169 113 117 82 60 I 60 72899 
151 105 153 106 164 101 45 I 100 71333 
110 70 120 80 108 70 47 I 100 73661 
138 80 120 70 121 65 43 II 50 71554 
120 70 140 90 110 70 32 I 90 72410 
120 80 134 87 117 76 43 I 100 72564 
110 70 127 92 106 68 37 I 90 27617 
96 56 100 70 104 76 42 I 80 72418 
130 92 120 74 110 80 37 I 80 72099 
117 84 172 128 124 88 60 II 100 68416 
160 127 127 92 131 82 35 I 100 68449 
146 108 124 90 118 82 38 l 100 68504 
148 98 112 78 118 72 42 II 100 68900 
114 74 114 76 112 76 34 l 100 72830 
120 70 110 80 120 74 100 l 100 73449 
120 80 127 92 118 76 55 l 80 78955 
 
